



### MALTA MEDICINES AUTHORITY - TOPRA TRAINING PROGRAMME 13th and 14th March

## Introduction to EU Regulatory Procedures

To provide an informative and interactive programme of information covering regulatory affairs activities from start to end of medicinal product lifecycle

#### Day ONE

0830-0900       Registration         0900-0915       Introduction and aims of the training         0915-0945       The EU regulatory environment and the role of regulatory affairs         0945-1030       Drug development and life-cycle pathways         •       Strategy / scientific advice         •       Nonclinical development         •       Clinical programme support         •       Manufacturing / process development         •       Preparation and management of the RA submission         •       Life cycle support         1030       Coffee         1045-1200       The importance of nonclinical safety studies and how the data are used in regulatory submissions         1200-1300       Drug substance, drug product and manufacturing data         1300       Lunch         1345-1430       Clinical data requirements for different types of products         1430-1600       Supporting clinical trials         The links between the studies, the IMPD and the CTD         1600-1630       Summary session         1630-1800       Case Study 1: Early development support – nonclinical and clinical	
0915-0945The EU regulatory environment and the role of regulatory affairs0945-1030Drug development and life-cycle pathways• Strategy / scientific advice • Nonclinical development • Clinical programme support • Manufacturing / process development • Preparation and management of the RA submission • Life cycle support1030Coffee1030The importance of nonclinical safety studies and how the data are used in regulatory submissions1200-1300Drug substance, drug product and manufacturing data1300Lunch1345-1430Clinical data requirements for different types of products1430-1600Supporting clinical trials The links between the studies, the IMPD and the CTD1600-1630Summary session	
0945-1030Drug development and life-cycle pathways• Strategy / scientific advice • Nonclinical development • Clinical programme support • Manufacturing / process development • Preparation and management of the RA submission • Life cycle support1030Coffee1045-1200The importance of nonclinical safety studies and how the data are used in regulatory submissions1200-1300Drug substance, drug product and manufacturing data1300Lunch1345-1430Clinical data requirements for different types of products1430-1600Supporting clinical trials The links between the studies, the IMPD and the CTD1600-1630Summary session	
<ul> <li>Strategy / scientific advice</li> <li>Nonclinical development</li> <li>Clinical programme support</li> <li>Manufacturing / process development</li> <li>Preparation and management of the RA submission</li> <li>Life cycle support</li> <li>1030</li> <li>Coffee</li> <li>1045-1200</li> <li>The importance of nonclinical safety studies and how the data are used in regulatory submissions</li> <li>1200-1300</li> <li>Drug substance, drug product and manufacturing data</li> <li>1300</li> <li>Lunch</li> <li>1345-1430</li> <li>Clinical data requirements for different types of products</li> <li>1430-1600</li> <li>Supporting clinical trials</li> <li>The links between the studies, the IMPD and the CTD</li> <li>1600-1630</li> <li>Summary session</li> </ul>	
<ul> <li>Nonclinical development</li> <li>Clinical programme support</li> <li>Manufacturing / process development</li> <li>Preparation and management of the RA submission</li> <li>Life cycle support</li> </ul> 1030 Coffee 1045-1200 The importance of nonclinical safety studies and how the data are used in regulatory submissions 1200-1300 Drug substance, drug product and manufacturing data 1300 Lunch 1345-1430 Clinical data requirements for different types of products 1430-1600 Supporting clinical trials The links between the studies, the IMPD and the CTD 1600-1630 Summary session	
<ul> <li>Clinical programme support</li> <li>Manufacturing / process development</li> <li>Preparation and management of the RA submission</li> <li>Life cycle support</li> <li>1030</li> <li>Coffee</li> <li>1045-1200</li> <li>The importance of nonclinical safety studies and how the data are used in regulatory submissions</li> <li>1200-1300</li> <li>Drug substance, drug product and manufacturing data</li> <li>1300</li> <li>Lunch</li> <li>1345-1430</li> <li>Clinical data requirements for different types of products</li> <li>1430-1600</li> <li>Supporting clinical trials The links between the studies, the IMPD and the CTD</li> <li>1600-1630</li> <li>Summary session</li> </ul>	
<ul> <li>Manufacturing / process development</li> <li>Preparation and management of the RA submission</li> <li>Life cycle support</li> <li>1030</li> <li>Coffee</li> <li>1045-1200</li> <li>The importance of nonclinical safety studies and how the data are used in regulatory submissions</li> <li>1200-1300</li> <li>Drug substance, drug product and manufacturing data</li> <li>1300</li> <li>Lunch</li> <li>1345-1430</li> <li>Clinical data requirements for different types of products</li> <li>1430-1600</li> <li>Supporting clinical trials</li> <li>The links between the studies, the IMPD and the CTD</li> <li>1600-1630</li> <li>Summary session</li> </ul>	
<ul> <li>Preparation and management of the RA submission</li> <li>Life cycle support</li> <li>1030 Coffee</li> <li>1045-1200 The importance of nonclinical safety studies and how the data are used in regulatory submissions</li> <li>1200-1300 Drug substance, drug product and manufacturing data</li> <li>1300 Lunch</li> <li>1345-1430 Clinical data requirements for different types of products</li> <li>1430-1600 Supporting clinical trials The links between the studies, the IMPD and the CTD</li> <li>1600-1630 Summary session</li> </ul>	
<ul> <li>Life cycle support</li> <li>Coffee</li> <li>1045-1200 The importance of nonclinical safety studies and how the data are used in regulatory submissions</li> <li>1200-1300 Drug substance, drug product and manufacturing data</li> <li>1300 Lunch</li> <li>1345-1430 Clinical data requirements for different types of products</li> <li>1430-1600 Supporting clinical trials The links between the studies, the IMPD and the CTD</li> <li>1600-1630 Summary session</li> </ul>	
1030Coffee1045-1200The importance of nonclinical safety studies and how the data are used in regulatory submissions1200-1300Drug substance, drug product and manufacturing data1300Lunch1345-1430Clinical data requirements for different types of products1430-1600Supporting clinical trials The links between the studies, the IMPD and the CTD1600-1630Summary session	
1045-1200The importance of nonclinical safety studies and how the data are used in regulatory submissions1200-1300Drug substance, drug product and manufacturing data1300Lunch1345-1430Clinical data requirements for different types of products1430-1600Supporting clinical trials The links between the studies, the IMPD and the CTD1600-1630Summary session	
1200-1300Drug substance, drug product and manufacturing data1300Lunch1345-1430Clinical data requirements for different types of products1430-1600Supporting clinical trials The links between the studies, the IMPD and the CTD1600-1630Summary session	
1300       Lunch         1345-1430       Clinical data requirements for different types of products         1430-1600       Supporting clinical trials         The links between the studies, the IMPD and the CTD         1600-1630       Summary session	
1345-1430       Clinical data requirements for different types of products         1430-1600       Supporting clinical trials         The links between the studies, the IMPD and the CTD         1600-1630       Summary session	
1430-1600     Supporting clinical trials       The links between the studies, the IMPD and the CTD       1600-1630     Summary session	
The links between the studies, the IMPD and the CTD       1600-1630     Summary session	
1600-1630 Summary session	
1630-1800       Case Study 1: Early development support – nonclinical and clinical	
1800   Reception and Team Quiz	





### MALTA MEDICINES AUTHORITY - TOPRA TRAINING PROGRAMME 13th and 14th March

# Day TWO

Time	Торіс
0900-0915	Overview of Day 1 and aims for Day 2
0915-1000	Malta Medicines Authority's view of EU Procedures and factors for success
1000-1030	EU submissions procedures
1030	Coffee
1045-1100	EU submissions procedures team task
1100-1130	The centralised procedure: common challenges
1130-1200	DCP and MRP: common challenges
1200-1230	Generic products and biosimilars
1230-1300	Feedback session
1300	Lunch
1345-1430	Lifecycle management (I): Regulatory Compliance
	<ul> <li>The MA Holders obligations and some nightmare examples of how not to do this</li> <li>When is a variation not a variation?</li> </ul>
1430-1515	Workshop – Variations
1515-1615	Safe use of medicines by the patient:
	<ul> <li>The importance of the SPC / PIL / Label</li> <li>How this links with claims</li> </ul>
1615-1715	Workshop: Regulatory Strategies
1715-1745	Questions / Training review
1745-1800	Closing